Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047632 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
A Phase 3 study, sponsored by InterMune.
- Terminated
- Registry status
- Phase 3
- Development phase
- 847
- Enrollment target
NCT00047632 is a Phase 3 study that was terminated before completion, run by InterMune. The registered enrollment target is 847 participants.
The verdict
NCT00047632, a Phase 3 study, was terminated before completion, sponsored by InterMune.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 847 participants
- Enrollment target
Study Summary
The purposes of this study are to determine: 1) if treatment with interferon gamma-1b plus standard chemotherapy (carboplatin and paclitaxel) can increase the overall survival of patients with advanced ovarian or primary peritoneal carcinoma compared with chemotherapy alone; 2) how effective interferon gamma-1b plus standard chemotherapy is in preventing the progression or return of cancer; 3) the effects on quality of life; and 4) the safety of interferon gamma-1b combined with standard chemotherapy compared to chemotherapy alone.
Interventions
- DRUG Interferon gamma-1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 847 participants |
| Start Date | 2001-10 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047632
The ClinicalTrials.gov registry entry for NCT00047632 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 847 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InterMune, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon gamma-1b is the first listed.
NCT00047632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047632 about?
NCT00047632 is a clinical study titled "Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer". The purposes of this study are to determine: 1) if treatment with interferon gamma-1b plus standard chemotherapy (carboplatin and paclitaxel) can increase the overall survival of patients with advanced ovarian or primary peritoneal carcinoma compared with chemotherapy alone; 2) how effective interfe...
What is the current status of trial NCT00047632?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 847 participants. The study started on 2001-10. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00047632?
The interventions under investigation include: Interferon gamma-1b (DRUG).
Who is sponsoring clinical trial NCT00047632?
This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.